The predictive role of ERCC1 status in Oxaliplatin based neoadjuvant therapy for metastatic colorectal cancer (mCRC) to the liver

Ravit Geva, M.D.
Head, Gastrointestinal malignancies Service Head, Research Unit, Division of Oncology, Tel-Aviv Sourasky Medical Center